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Vascular-endothelial growth-factor (receptor) (VEGF)(R)-inhib-
iting agents – sunitinib [1–3], sorafenib [4,5], pazopanib [2,6],
bevacizumab [7,8], axitinib [5] and tivozanib [9,10] – have
changed the therapeutic landscape in metastatic renal-cell
carcinoma (mRCC). Five out of six agents have been approved
for either first-line (sunitinib, pazopanib and bev-
acizumab + interferon-alpha) or second-line (sorafenib, axiti-
nib) treatment of metastatic or advanced RCC. With these
novel strategies, the median overall survival of patients has
increased considerably, often, however, at the expense of
chronic side-effects. Common treatment-related side-effects
include: (1) general symptoms such as fatigue and asthenia,
(2) gastrointestinal symptoms such as diarrhoea and stomati-
tis, (3) skin toxicities, (4) cardiovascular toxicities and (5) a
variety of laboratory abnormalities. Some of these side-effects
are clinically highly relevant because they may jeopardise the
patient’s safety or quality of life, while others may have little
clinical relevance. Treating physicians need to be aware of po-
tential side-effects that may occur, how to prevent and/or
manage them, and the clinical implications for the ongoing
treatment. This is of paramount importance since dose
reductions and treatment discontinuations may significantly
affect the outcome [11].
2. Incidence of toxicities associated with VEGF
inhibitors
Toxicities reported from VEGFR inhibitors in mRCC are out-
lined in Table 1. Among general symptoms, fatigue (and/or
asthenia) has been most commonly reported for sunitinib
(up to 63% all grades; grade P3: 17%), followed by axitinib
(all grades 39%, grade P3: 11%) and sorafenib (all grades
37%; gradeP3: 5%). A high incidence of fatigue has also been
reported from the combination of bevacizumab + interferon-
alpha (IFNa). However, the incidence of fatigue appears to
be low in patients being treated with bevacizumab alone
[12,13]; thus, this side-effect may be attributed to IFNa ratherthan bevacizumab. Interestingly, the newest VEGFR–tyrosine
kinase inhibitor (TKI) tivozanib appears to have little effect
on fatigue levels (all grades: up to 18%, grade P3: 5%).
Gastrointestinal side-effects are extremely common in pa-
tients on VEGFR–TKI treatment. In particular, sunitinib and
axitinib were shown to cause reduced appetite and/or anorex-
ia in up to 34% of the patients. In the case of sunitinib, this
may be caused partly by the high incidence of stomatitis
and/or dysgeusia (30% and 46%, respectively). Diarrhoea is an-
other frequent gastrointestinal toxicity: high incidences of all
grades of diarrhoea were reported from patients on sunitinib
(61%), sorafenib (53%), pazopanib (63%) and axitinib 55%,
again with quite a favourable profile for tivozanib (22%).
The most common skin toxicities caused by VEGFR inhib-
itors are hand–foot syndrome (HFS), skin- and/or hair-depig-
mentation and rash. The highest incidence of all grades of
HFS has been reported from sorafenib (51%) and sunitinib pa-
tients (50%), with a higher grade 3 + 4 HFS incidence in sorafe-
nib patients (16%). Similarly, sorafenib was shown to cause
rash in up to 32% of patients (all grades). Hair and/or skin
depigmentation is commonly observed in patients on pazop-
anib (up to 38%) and sunitinib (up to 27%).
Among the group of cardiovascular, lung and laryngeal
side-effects, hypertension is the most common (up to 46%).
Hypertension has been observed with all of these agents
and has been considered a fairly reliable biomarker for re-
sponse, progression-free survival (PFS) and overall survival
(OS) [14]. The highest incidence of grades 3 + 4 hypertension
has been observed with tivozanib (26%). Cardiac side-effects
include congestive heart failure (sunitinib: 13%) and ischae-
mia or myocardial infarction (sorafenib: 3%; bev-
acizumab + interferon-alpha 1%). Bleeding events, most
commonly epistaxis, have been observed in patients treated
with bevacizumab + IFN, sunitinib and sorafenib (33%, 18%
and 15%, respectively). While dyspnoea is a common side-ef-
fect of mTOR-inhibitors, the incidence is low in patients with
VEGFR inhibitors. No direct effect of these agents on lung
tissue has been reported so far; thus, the occurrence of dysp-
noea might be a secondary event due to lung metastases or
Table 1 – Toxicities reported from phase III trials (%).
(Continued on next page)
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 7 2 –1 9 1 173oedema as a result of high-grade hypertension or congestive
heart failure. In contrast, dysphonia is a common side-effect
of new-generation TKIs such as axitinib (31%) and tivozanib
(22%).
The incidence of grade 3 + 4 myelotoxicity is low with VEG-
FR inhibitors when compared to classical cancer treatment
such as chemotherapy. Nevertheless, multikinase inhibitors,particularly sunitinib, may induce grade 3 + 4 anaemia (8%),
neutropenia (18%), thrombocytopenia (9%) and lymphopaenia
(18%). Infections, however, have not been reported yet.
Various metabolic and laboratory abnormalities have been
shown to occur in patients treated with VEGFR inhibitors.
These include renal and electrolyte abnormalities such as cre-
atinine increase (up to 70%), proteinuria (71%), abnormalities
Table 1 (continued)
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37%, 50%, 31% and 59%, respectively. In addition, pazopanib,
sunitinib and tivozanib in particular were shown to cause in-
creased levels of bilirubin, alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) in up to 36%, 60% and
61% of the patients, respectively. In the case of tivozanib,
international normalised ratio (INR) and partial thrombo-
plastin time (PTT) abnormalities were also reported (82%
and 53%, respectively). Sunitinib, sorafenib and tivozanib
were shown to increase amylase and lipase levels in approx-
imately 50% of patients. Finally, the induction of hypothyroid-
ism is an observation that may have been underreported in
the pivotal trials; in later analyses, up to 36% of patients
was shown to develop hypothyroidism [15]. As with hyperten-
sion, the occurrence of hypothyroidism has been linked to a
better outcome [15,17].
3. The severity of side-effects and their impact
on outcome
The occurrence of grade 3 + 4 toxicities, and to some extent
also toxicities of lower grades, may tempt clinicians to reduce
the dose, or to interrupt or discontinue treatment. Table 2 out-
lines the incidence of dose reductions and interruptions, the
rate and most common reasons for treatment discontinua-
tions, as well as the most common toxicities that have ledto death. Dose reductions occurred in up to 51% of sunitinib
patients, 52% of sorafenib patients, 44% of pazopanib pa-
tients, 31% of axitinib patients and 14% of tivozanib patients,
while no dose reductions of bevacizumab were permitted in
the Bevacizumab plus interferon alfa-2a for treatment of met-
astatic renal cell carcinoma: a randomised, double-blind
phase III trial (AVOREN) and CALGB bevacizumab trials. Sim-
ilarly, dose interruptions and treatment delays were required
in 38% of sunitinib patients, 80% sorafenib patients, 62% bev-
acizumab + IFN patients and 77% of axitinib patients. In con-
trast, the number of patients with dose interruptions was
considerably lower in tivozanib patients (18%). Both dose
reductions and treatment interruption may help to prevent
or manage treatment-associated side-effects. However, sev-
eral authors have shown that higher relative dose intensities
were associated with better outcome. A pharmacodynamic/
pharmakokinetic analysis including six sunitinib trials re-
vealed that response rates, time to progression and overall
survival increased with the mean daily exposure to sunitinib
[11]. Similarly, intra-patient dose-escalated sorafenib was
shown to exert promising antitumour activity and led to a
complete/partial response (CR–PR) rate of 48%, with eight
out of 44 patients achieving complete remission [18]. Finally,
Rini et al. could demonstrate in a randomised phase II study
that axitinib dose titration significantly improved overall re-
sponse rates when compared to placebo in patients eligible
Table 2 – Dose reductions and treatment discontinuation due to adverse events.
Sunitinib [1–3] Sorafenib [4,5] Pazopanib [2,6] Bevacizumab [7,8] Axitinib [5] Tivozanib [9,10]
Dose reduction
due to AEs (%)
32 [1]
51 [2]
50 [3]
13 [4]
52 [5]
44 [2] Not permitted for
bevacizumab
31 8 [9]
13.9 [10]
Dose
interruptions
(treatment delays)
38 [1] 21 [4] for
dermatological
events, 80 for GI
events [5]
nr nr [7]
61.7 [8]
77 4 [9]
18 [10]
Discontinuation
due to AEs
8 [1]
19 [2]
10 [4]
8 [5]
12 [6]
24 [2]
28 [7] any
19 [7]
bevacizumab
23 [8]
4 9 [9]
4 [10]
Most common
reason
for
discontinuation
Cytopaenia [2] Constitutional [4],
gastrointestinal
[4], dermatologic
[4], respiratory
tract symptoms
[4]
HFS [5], diarrhoea
[5], asthenia [5]
Liver events [2] nr Fatigue, and
transient
ischaemic attack
nr [9,10]
AEs leading to
hospitalisation
34 [4] Nr nr nr nr [9,10]
TX-related death
or non-PD related
deaths
Renal failure [1]
n = 1
Gastric
haemorrhage [1]
n = 1
Respiratory
failure [1] n = 1
Sudden death [1]
n = 1
2 death from
cardiac
ischaemia/
infarction [4]
2 death [5] from
tumour necrosis
causing
retroperitoneal
bleeding and n = 1
GI bleeding
4 [6]
ischaemic stroke,
hepatic failure,
rectal
haemorrhage,
peritonitis and
bowel perforation
2 [7] bleeding
events n = 2, GI
perforation n = 1,
myocardial
infarction n = 1
atrial fibrillation
n = 1
pneumonia n = 1
hepatic failure
(history of active
hepatitis B)
n = 3 [8]
0 n [9]=8/272
ischaemic stroke
n = 2, acute
coronary
syndrome, acute
respiratory
failure, cerebral
vascular accident,
hypotension and
pulmonary
embolism all n = 1
nr [10]
nr, not reported.
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mRCC patients is to have a balanced approach to maintaining
both dose intensity and safety of the patient.
4. Reasons for and incidence of dose
adjustments and treatment discontinuation by
agent
4.1. Sunitinib
In the final analysis of sunitinib versus IFN-alpha [3], 51% and
19% of sunitinib patients were reported to have required dose
reductions or treatment discontinuation, respectively, be-
cause of adverse events. Causes of death apart from disease
progression included acute renal failure (n = 1), gastric haem-
orrhage (n = 1), respiratory failure (n = 1) and sudden death
(n = 1). In the COMPARZ trial, the most common reason for
sunitinib discontinuation was cytopaenia (3%).
4.2. Pazopanib
In the pivotal pazopanib trial [6] 33% and 4% of patients expe-
rienced grade 3 and 4 toxicities, respectively. The adverse
event (AE) profile was similar in treatment-naı¨ve and cyto-
kine-pretreated patients, although discontinuation rates be-
cause of AEs were higher in the cytokine-pretreated (19%)
compared with the treatment-naı¨ve patients (12%). Arterial
thromboembolic events occurred in 3% of pazopanib patients
– myocardial infarction or ischaemia 2%, cerebrovascular acci-
dent <1% and transient ischaemic attack (TIA) <1% – compared
with none in the placebo arm. The incidence of all-grade
haemorrhagic events was 13% in the pazopanib arm versus
5% in the placebo arm. Deaths from adverse events were re-
ported in 4% of pazopanib patients and in 3% in the placebo
arm. Four pazopanib patients (1%) had fatal adverse events,
including ischaemic stroke, abnormal hepatic function, rectal
haemorrhage and peritonitis/bowel perforation. In the COM-
PARZ trial [2] dose reductions and treatment discontinuations
occurred in 44% and 24% of patients, respectively. The most
common reasons for pazopanib discontinuation were liver
events (6%).
4.3. Sorafenib
In the TARGET trial [4] 10% of sorafenib patients had to dis-
continue the treatment, mostly because of constitutional,
gastrointestinal, dermatological or pulmonary upper respira-
tory tract symptoms. Dose reductions occurred in 13% of
sorafenib patients versus 3% of placebo patients (P < 0.001),
and dose interruptions because of adverse events occurred
in 21% of sorafenib patients versus 6% of placebo patients
(P < 0.001). Dose interruptions were mostly because of HFS,
rash or diarrhoea. Cardiac ischaemia occurred in 12 sorafenib
patients (3%) and two patients in the placebo groups (<1%),
(P = 0.01). Bleeding was more frequent in sorafenib than in
placebo patients (15% versus 8%, respectively). In the axitinib
phase III trial [5], the most frequent grade-3 and -4 adverse
events associated with sorafenib were HFS, hypophosphata-
emia, lipase elevation and hypertension. Two treatment-re-
lated deaths occurred in sorafenib patients and were causedby necrosis with retroperitoneal bleeding and gastrointestinal
haemorrhage.
4.4. Bevacizumab + IFN
In the AVOREN trial [7], serious adverse events occurred in
29% of patients who received bevacizumab versus 16% of
those who did not. Similarly, AEs requiring treatment discon-
tinuation were more frequent in bevacizumab-treated pa-
tients versus placebo patients (28% versus 12%). Grade 3 and
4 AEs in patients who received bevacizumab included four
gastrointestinal perforations (1%; grade 4: n = 3) and 10
thromboembolic events (3%; grade 4, n = 4). Moreover, seven
(2%) and 5% of bevacizumab patients discontinued treatment
because of hypertension and proteinuria, respectively. Deaths
due to AEs were reported in 2% of patients who received bev-
acizumab and 2% who did not. Three deaths (<1%) among the
patients who received bevacizumab (n = 2 bleeding events and
n = 1 gastrointestinal perforation) were thought to be associ-
ated with treatment. The other causes of death of bev-
acizumab-treated patients included myocardial infarction,
atrial fibrillation, pneumonia, hepatic failure (in a patient
with a history of hepatitis B) and staphylococcal sepsis.
In the CALGB trial [8] 80% of patients receiving bev-
acizumab experienced grade P3 toxicities compared with
63% IFN patients (P < 0.001). Bevacizumab resulted in signifi-
cantly more grade P3 hypertension (11% versus 0), anorexia
(17% versus 8%), fatigue (37% versus 30%) and proteinuria
(15% versus <1%). There were four treatment-related deaths
in the IFN arm and three in the bevacizumab arm.4.5. Axitinib
In the axitinib phase III trial [5], the most common AEs of
grade P3 were hypertension, diarrhoea and fatigue; 32% of
axitinib patients had elevations in thyroid-stimulating hor-
mone (TSH) and 27% required initiation or dose adjustments
of thyroid hormone replacement. No treatment-related
deaths occurred in the axitinib arm.4.6. Tivozanib
In the phase II randomised discontinuation trial on tivozanib,
the most common treatment-related toxicities were hyper-
tension and dysphonia which occurred in 45% and 22% of pa-
tients, respectively. Grade 3 and 4 toxicities were rare and
included hypertension (grade 3: 11%, grade 4: 1%) and labora-
tory abnormalities (5%). Dose reductions and interruptions
were deemed necessary in 8% and 4% of patients, respec-
tively. Treatment discontinuation because of adverse events
occurred in 9% of patients. Causes of death that were not
attributed to disease progression included ischaemic stroke
(n = 2), coronary syndrome, respiratory failure, cerebral vascu-
lar accident, hypotension and embolism (n = 1 each); however,
none of these were associated with tivozanib treatment.
Understanding the pathophysiology of individual toxicities,
and developing proactive strategies for their prevention and
treatment are important aspects of disease management and
may avoid dose reductions and treatment discontinuation.
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(involved targets) and management
Targeted agents differ regarding their side-effect profile, and
these differences may be attributed to the mode of action;
the incidence and severity of side-effects may depend on
the number of inhibited targets (single versus multikinase
inhibitors), the type of inhibited target (VEGF inhibition ver-
sus platelet-derived growth factor, PDGF, inhibition versus
Flt-3 inhibition, etc.) and the strength of target inhibition
(affinity to the tyrosine kinase, ‘on- and off-target’ toxicities).
While some toxicities have been linked to the inhibition of a
specific target, e.g. hypertension and VEGF, the association
of other side-effects with a particular target is less clear (e.g.
stomatitis, diarrhoea). Moreover, the incidence and severity
of side-effects may differ between patient populations
depending on single-nucleotide polymorphisms.5.1. Fatigue, asthenia
5.1.1. Mechanisms
Fatigue and to a slight extent asthenia are frequent symptoms
in patients undergoing treatment with VEGF inhibitors. In
1998, Cella and colleagues described fatigue as a ‘subjective
state of overwhelming and sustained exhaustion and decreased
capacity for physical and mental work that is not relieved by rest’
[20]. Fatigue induced by VEGF inhibitors may indeed include
more symptoms than tiring easily. Patient’s description of
what their fatigue involves includes a loss of social interest,
reduced voluntariness for physical activity, cognitive disor-
ders, reduced appetite and depressive symptoms. Together,
these symptoms have been described as sickness behaviour,
a common status in patients with acute or chronic diseases
[21]. In patients treated with VEGF inhibitors, many factors
appear to contribute to fatigue and sickness behaviour. These
include several biological processes related to the patient
and/or the disease in which inflammation appears to have a
major role. Moreover, treatment-related side-effects may con-
tribute to fatigue and asthenia.
The underlying mechanisms appear to involve many as-
pects: (1) the individual genome of the patient, (2) disease-re-
lated factors, either biological or as a result of behavioural
and psychological factors that may arise during the disease,
(3) cancer treatment itself, which may induce fatigue either
on the basis of the specific mode of action or secondarily by
leading to side-effects that may be associated with the symp-
tom of fatigue.
Several studies have investigated the relationship between
genomic markers and fatigue. An association was found be-
tween functional interleukin-6 (IL-6) polymorphism and fati-
gue in patients and their relatives [22], while Aouizerat and
colleagues found evidence for a genetic association between
tumour necrosis factor alpha (TNFa) and the severity of sleep
disturbances and morning fatigue [23]. Furthermore, single-
nucleotide polymorphisms (SNPs) of several cytokines –
including Interleukin-1b, IL-1RN and IL-10 – showed associa-
tions with fatigue levels in lung cancer patients [24]. So far,
no genomic markers for fatigue have been identified in pa-
tients undergoing VEGF inhibitor treatment.Fatigue has also been strongly correlated with depression
in cancer patients [25], and increased stress-induced inflam-
matory responses were observed in patients with major
depression and stress [26]. Moreover, acute psychological
stress was shown to influence pro-inflammatory cytokines
[27]. Finally, physical inactivity and increased body mass in-
dex have been associated with fatigue in patients with breast
cancer [28]. Again, no data have been obtained so far with re-
spect to patients treated with VEGF inhibitors.
Many tumour types have been shown to promote progres-
sion though inflammatory cells [29]. Chemokines and cyto-
kines were shown to attract immune cells to tumour cells
[30], thereby leading to immune-cell dysfunction [31]. Re-
search on neuro-immune signalling has linked pro-inflam-
matory cytokines with the development of fatigue. For
instance, sickness has been shown to be triggered by IL-1a
and b, TNFa and IL-6 [32–34]. Although no studies have been
undertaken in patients undergoing anti-VEGF-treatment, IL-
6 levels have been linked to disease progression in patients
with mRCC [35].
Cancer treatment itself is known to induce fatigue. Induc-
tion of chronic inflammation has also been recognised as a
treatment-related factor that may induce fatigue through
pro-inflammatory cytokines produced by monocytes [36].
Wang et al. measured markers of inflammation in patients
with gastrointestinal cancers undergoing chemotherapy and
their relationship with fatigue. They found that serum con-
centrations of TNF-R1 were associated with the severity of fa-
tigue [37]. Similar findings have been reported by various
other authors with regards to C-reactive protein (CRP) levels,
IL-6, etc. It is currently unknown as to whether VEGFR inhib-
itors can trigger fatigue through inflammation.
Various side-effects associated with VEGF inhibitors may
contribute to fatigue and sickness behaviour; persistent fati-
gue is a common symptom of patients with hypothyroidism
[38] and several VEGF inhibitors have been shown to induce
hypothyroidism (Table 1). Similarly, hypophosphataemia is
frequently observed in patients treated with VEGF inhibitors.
Although a low serum phosphate level does not necessarily
correlate with clinically relevant total body phosphate deple-
tion, it should be considered that hypophosphataemia may
cause muscle weakness [39]. Muscular dysfunction has also
been shown to involve the heart [40] by causing myocardial
changes and a reversible reduced sensitivity to catechola-
mines [40]. Muscle weakness may also be explained by an im-
paired muscle glucose uptake. Muscle activity involves an
increased rate of glucose uptake in the contracting muscle.
This is enabled by glucose transporter recruitment [41]. Mult-
ikinase inhibitors may interfere with signals required for this
process, such as protein kinase C, nitric oxide, etc. [42]. Fur-
thermore, TKI-induced hypoglycaemia may also contribute
to muscular weakness. Sunitinib, for instance, was shown
to decrease blood glucose levels [43]. In a clinical study that
sought to distinguish between a central and peripheral cause
of fatigue, Yavuszen et al. [44] found that patients with
cancer-related fatigue had a greater central fatigue, indicated
by shorter endurance time. Central fatigue has been linked to
a loss of voluntarily activated muscles because of mecha-
nisms proximal to the neuromuscular junction. On the other
hand, muscle fatigue may have a peripheral cause, e.g. due to
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could demonstrate that treatment with sorafenib exacerbates
excessive muscle loss and that this loss increased during the
course of treatment. A possible explanation for this phenom-
enon is that VEGF inhibition leads to downstream inhibition
of AKT and mTOR, which are of paramount importance for
skeletal muscle hypertrophy and muscle protein synthesis
[46].
Finally, malnutrition as a result of VEGF-inhibitor-induced
anorexia, anaemia and dehydration caused by diarrhoea may
account for the high incidence of fatigue, asthenia and sick-
ness behaviour in patients undergoing VEGF inhibitor
treatment.
5.1.2. Management
Effective treatment for fatigue includes pharmaceutical and
non-pharmaceutical interventions.
5.1.2.1. Non-pharmacological interventions. Patterson and
colleagues [47] recently reviewed studies that looked at the
impact of eight different types of intervention on fatigue lev-
els. These interventions included (1) psycho-education, (2)
cognitive behavioural therapy, (3) exercise combined with
education and support, (4) exercise alone, (5) acupressure,
(6) energy conservation and activity management, (7) relaxa-
tion breathing exercises and (8) distraction. With the excep-
tion of cognitive behavioural therapy, all of the above-
mentioned non-pharmacological interventions were found
to effectively reduce fatigue in patients with various diseases.
In particular the impact of exercise has been well studied in
patients with cancer-related fatigue. A Cochrane analysis
[48] recently revealed that among 56 studies including 4068
participants aerobic exercise significantly reduced fatigue
while resistance training and alternative forms of exercise
did not. In contrast, Strasser et al. [49] performed a meta-
analysis on the impact of resistance training in cancer survi-
vors and found an association between resistance training
and positive effects on muscular function and body composi-
tion. Finally, a meta-analysis on exercise programmes for
cancer patients revealed an impact of these interventions
on physical functioning and quality of life [50].
5.1.2.2. Pharmacological interventions. The finding that fa-
tigue is linked to the activation of pro-inflammatory cytokines
has led to the hypothesis that agents inhibiting these cytokines
may reduce fatigue levels. In a randomised placebo-controlled
trial [51] the immunosuppressant etanercept, a recombinant
TNFa receptor fusion protein, enabled a significant improve-
ment in fatigue (mean FACIT-F improvement 5.5 versus 1.9;
P < 0.0001; 95%CI 1.6–4.5) in patients with psoriasis. Similarly,
the monoclonal antibody infliximab was shown to signifi-
cantly reduce fatigue levels in breast cancer survivors with per-
sistent fatigue [52]. Other pharmacological interventions may
include psychostimulants such as methyphenidate [53]. The
relationship between inflammation and depression has also
generated the hypothesis that the essential amino acid trypto-
phan might have a role. Tryptophan is a precursor for seroto-
nin, and patients receiving immunotherapy were shown to
have a fall in tryptophan plasma levels [54]. Another strategy
that might interfere positively with inflammation-inducedfatigue is the administration of thyrotropin-releasing hormone
(TRH). TRH was shown to be involved in the biological pro-
cesses of cytokine-induced sickness behaviour [55], and the
administration of TRH has been associated with a significant
improvement in fatigue levels, sleep disturbances and quality
of life. These effects were accompanied by a decrease in CRP
levels and an improvement in energy levels [55]. Attempts to
interfere with muscle wasting have been made with L-carnitine
supplementation, which was shown to have beneficial effects
by improving nitrogen balance via increased protein synthesis
or reduced protein degradation, inhibition of myonuclear
apoptosis and interference with inflammation. Finally, any
intervention that reduces the incidence and severity of fati-
gue-inducing side-effects may secondarily help to reduce fati-
gue levels: this includes control of anaemia, diarrhoea,
hypothyroidism, hypophosphataemia, congestive heart fail-
ure and malnutrition.
5.2. Hypertension
5.2.1. Mechanism
Hypertension is a common and dose-dependent side-effect of
all VEGF inhibitors. Classical known risk factors for hyperten-
sion failed to predict the development of hypertension in pa-
tients undergoing anti-VEGF treatment [56]. The development
of hypertension in patients undergoing anti-VEGF treatment
has mechanistically been linked to the pathophysiology of
pre-eclampsia in pregnant women. In both cases, a deficient
production of the vasodilator nitric oxide (NO) from endothe-
lial cells and/or decreased NO levels seems to play a central
role [57,58]. VEGF activates endothelial NO synthase through
AKT [59], and a VEGF antibody has been shown to inhibit this
process leading to a decrease in NO levels [58]. Inhibition of
NO may cause vasoconstriction and hypertension [56,60]. An
additional aspect of impaired NO functioning is related to
its role in the control of renal function and salt sensitivity.
NO was found to act as a regulator of pressure-natriuresis
and plays an important role in the regulation of blood flow
to the renal medulla and in the tubular regulation of sodium
excretion [56]. It has therefore been concluded that inhibition
of NO synthase may result in hypertension through its role in
the control of renal water and sodium excretion. Finally, other
mechanisms that may contribute to hypertension have been
described. High salt intake has been shown to increase lym-
phatic vessel growth through increased VEGF-C production.
Inhibition of VEGF-C by pan-VEGF inhibitors may therefore
decrease lymphatic vessel density and increase blood pres-
sure [61]. Apart from the impaired NO production, prostacyc-
lins may contribute to the development of hypertension
under anti-VEGF treatment. VEGF has been shown to activate
the production of the vasodilator prostacyclin (PGI2) [62], and
reduced levels of PGI2 metabolites were found in patients with
pre-eclampsia, suggesting a role for decreased VEGF levels.
Another mechanism that appears to trigger hypertension is
vascular rarefaction. Inhibition of VEGF signalling was found
to cause a loss of endothelial fenestration followed by regres-
sion of tumour vessels [63]. Similarly, normal capillaries in
healthy tissues were shown to regress after VEGF inhibition
[64]. Thus, a reduction in tissue microvessel density may in-
crease blood pressure through an increase in after-load. An
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resulting from glomerular ischaemia has also been discussed
as a potential mechanism for the development of hyperten-
sion. However, Kappers and colleagues demonstrated that a
sunitinib-induced increase in blood pressure is accompanied
by a decrease in renin [65]. The same group also showed that
sunitinib was associated with a considerable rise in endothe-
lin-1 levels. In a rat model, pretreatment with atrasentan, an
endothelin-A receptor antagonist, completely prevented a
TKI-induced rise in blood pressure [66].
5.2.2. Management
Patients undergoing VEGF inhibitor treatment should be
checked for existing blood pressure and informed about the
importance of monitoring and treating blood pressure. Home
monitoring has been recommended as a reasonable method
to closely monitor blood pressure. Recommendations regard-
ing the frequency of measurements vary between three times
daily [67] to once weekly [68]. Accepted thresholds for initiat-
ing antihypertensive treatment are blood pressures of P140/
90 mmHg and 130/80 in patients with diabetes or chronic re-
nal failure [67,69]. The selection of a specific antihypertensive
drug should be based on the general cardiovascular status of
the patient, as assessed by electrocardiogram (ECG) and echo-
cardiography before treatment [67]. According to the practice
guidelines for the management of arterial hypertension [70],
the choice of antihypertensive treatment should be based
on the underlying cardiovascular co-morbidity. Other recom-
mendations for optimal treatment may be based on consider-
ations of the underlying pathological mechanisms. As VEGF
inhibitors also induce proteinuria, angiotensin-converting en-
zyme (ACE) inhibitors may be considered appropriate: ACE
inhibitors were shown to improve nephrin expression and
to improve endothelial function [71]. Angiotensin inhibitors
as well as angiotensin-receptor blockers may have an addi-
tional advantage since they were shown to exert antitumour
activity (also discussed in section on proteinuria). Calcium-
channel blockers such as nifedipine may offer the (vascular)
advantage of VEGF secretion from coronary smooth muscles
cells [72]. In contrast, non-dihydropyridine calcium-channel
blockers such as verapamil or diltiazem should be avoided:
being Cytochrome P540 3A4 (CYP3A4) inhibitors, they may
interfere with the tumour drug metabolism. Finally, it is
important to inform the patient to withhold antihypertensive
medication in off-treatment periods, where blood pressure
mostly normalises.
5.3. Proteinuria
5.3.1. Mechanism
Although proteinuria has been understood as a classical on-
target side-effect, such as hypertension, little has been re-
ported from the pivotal RCC studies. This could be due either
to the lack of systematic assessment of proteinuria during the
trials or to a low incidence, leading to a drop-out from the tox-
icity tables. No data on proteinuria have been published in the
randomised trials of sunitinib, sorafenib, bevacizumab + IFNa
and axitinib; in contrast, proteinuria has been noted as a
common side-effect in the pazopanib and tivozanib trials tri-
als, with an all-grade incidence up to 71% and a grade 3 + 4incidence up to 15%. As proteinuria has been linked to VEGF
inhibition, it is likely that all of these agents induce protein-
uria to a considerable extent. Several mechanisms have been
summarised in a comprehensive review on proteinuria in-
duced by VEGF signalling inhibition by Izzedine et al. [73],
and include (1) inhibition of VEGF on podocytes which results
in loss of endothelial fenestrations in glomerular capillaries,
endotheliosis, loss of podocytes and proteinuria [74,75], (2)
an anti-VEGF treatment-induced glomerular endothelial cell
detachment and hypertrophy [76], (3) a subacute glomerular
thrombotic microangiopathy [73] and (4) an adaptive hyperfil-
tration response to nephrectomy [73].
5.3.2. Management
Any abnormal proteinuria may not only trigger loss of kidney
function, it also represents a considerable risk for renal dis-
ease and cardiovascular morbidities. In patients with chronic
renal disease, structural and functional cardiac changes have
been linked to persistent pressure and volume overload [77].
Moreover, strong association between proteinuria and subse-
quent risk of coronary artery disease have been confirmed in
a meta-analysis involving 169,949 patients; in this analysis,
the presence of proteinuria was associated with a 50% in-
creased risk for coronary artery events [78]. VEGF inhibitors
have enabled many patients to live long enough to experience
such additional drug-induced diseases. Thus, both regular
monitoring for proteinuria as well as thorough management
of proteinuria appears mandatory in patients under chronic
VEGF inhibitor treatment. It has been recommended that pa-
tients should be assessed for existing kidney disease prior to
the start of the treatment [73], and that a dipstick analysis
and/or quantitative protein test analysis be performed before
each cycle of VEGF inhibitor treatment. In the case of isolated
proteinuria of <1 g/L, anti-VEGF treatment might be contin-
ued along with continued monitoring. In the case of protein-
uria P1 g/L or proteinuria with microscopic haematuria, a
nephrologist should be involved who may decide on whether
to perform biopsy. Treatment recommendations include ACE
inhibitors or angiotensin-2 receptor antagonists which were
both shown to reduce proteinuria [79,80]. Additional mea-
sures may include salt restriction and the use of dexametha-
sone, which may stabilise the podocyte cytoskeleton [81].
5.4. Cardiac toxicities
5.4.1. Mechanism
Cardiac toxicities occurring under VEGFR inhibitors may be
the result of both on-target and off-target inhibition. Several
kinases inhibited by multikinase inhibitors such as VEGF, Hy-
poxia-inducible factor (HIF), PDGF and KIT are physiologically
highly relevant for the heart, and the inhibition of these ki-
nases may impair compensatory mechanisms [82–84]. HIF
inhibition, for instance, may cause cardiac toxicity since in
the cardiovascular system HIF-related gene products are
understood as mediators of myocardial response to acute or
chronic ischaemia, myocardial remodelling, peri-infarct vas-
cularisation and vascular permeability. Thus, inhibition of
these kinases may impair the myocardial response to acute
or chronic ischaemia [82–85]. Disruption of PDGF–platelet de-
rived growth factor receptor (PDGFR) signalling may lead to
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pressed on cardiac myocytes and endothelial cells. Suniti-
nib-induced inhibition of S6 kinase may lead to the release
of pro-apoptotic factor Apoptosis-regulator (BCL2) anatago-
nist of cell death, BCL2-associated X protein activation and
cytochrome C release and activation of the intrinsic apoptotic
pathway and cell death [86]. Disruption of KIT signalling may
cause cardiac damage by inhibiting repair mechanisms. KIT is
expressed on endothelial progenitor cells, and functioning of
the KIT receptor might be necessary for the mobilisation of
endothelial progenitor cells to sites of injury. Inhibition of
KIT was shown to aggravate myocardial remodelling and pre-
vent repair [87–89]. Disruption of VEGF–VEGFR signalling in
the heart may induce cardiac dysfunction by preventing com-
pensatory hypertrophy; VEGF is relevant to capillary density
in the myocardium and critical for stem-cell differentiation
into cardiomyocytes [90,91]. In the murine model, disruption
of VEGF–VEGFR signalling during imposition of the pressure
load was shown to reduce capillary density, which in turn
was associated with contractile dysfunction, fibrosis and
heart failure. Thus, inhibition of VEGF–VEGFR signalling in
the heart may become relevant to patients with poorly con-
trolled hypertension. Finally, TKI-induced changes to the thy-
roid function may cause cardiac toxicity. Triiodothyronine has
a direct effect on the cardiomyocytes. Any T3 depletion could
cause changes at the nuclear level of the myocyte level by
influencing T3-regulated transcription of genes that encode
Ca2+-ATPase exchanger, Na+/K+-ATPase and voltage-gated
potassium channels. Moreover, T3 exerts important non-nu-
clear functions on the myocyte which include ion channels
for sodium, potassium and calcium [92]. Finally, low serum
T3 levels have been shown to be the single and the most sig-
nificant predictor of cardiovascular and all-cause mortalities
in adults with heart disease [93]. Triiodothyronine also di-
rectly affects vascular smooth muscle cells, promoting relax-
ation [94]. Hypothyroidism was shown to increase vascular
resistance [94,95] and to exert endothelial dysfunction due
to reduced nitric oxide availability [96,97].
5.4.2. Management
The management of cardiac toxicities may vary among pa-
tients and may depend on the drug that has been used, poten-
tial existing co-morbidities and concomitant medications
that may trigger cardiac events. The clinical presentation
may vary as well: a decrease in left ventricular ejection frac-
tion was noticed in 13% of the patients in the sunitinib phase
III study [3]. In the target trial on sorafenib versus placebo, 3%
of patients experienced cardiac ischaemia or myocardial
infarction. Other investigators noticed arrhythmias and con-
duction disturbances, ST-segment or T-wave changes [84].
Based on the variety of clinical manifestations of cardiac tox-
icities, no general recommendation can be made. However,
this side-effect clearly requires a multidisciplinary approach
between oncologist and cardiologist. The risk of developing
a cardiac event during TKI treatment should be assessed prior
to treatment. On the other hand, patients with existing car-
diac co-morbidities should not be deprived of effective cancer
treatment. Early management of hypertension and protein-
uria appears mandatory to reduce the risk of a cardiac event
during TKI treatment. Congestive heart failure that developsunder TKI treatment is generally completely reversible but re-
quires treatment interruption and effective management [98].
TKI treatment can usually be resumed after recovery, but
should be initiated carefully with close monitoring of the pa-
tient. Cardiac ischaemia and myocardial infarction also re-
quire treatment interruption and cardiological care. Upon
recovery of the patient, the oncologist and cardiologist need
to discuss the conditions under which the patient might be
able to resume RCC treatment. The concomitant use of aspi-
rin and/or clopidrogel should not necessarily represent a con-
traindication; however, increased risks for haemorrhage need
to be carefully considered. In patients who have experienced
either congestive heart failure or myocardial ischaemia or
infarction, regular echocardiograms and electrocardiograms
should be obtained; the value of cardiac troponin T, Creatine
kinase (CK)-MB pro-B-type Natriuretic Peptide (BNP) is ques-
tionable. Many patients on TKI smay have increased serum
levels of one or all of these markers; however, for various rea-
sons, not all of them are clinically relevant. In asymptomatic
patients with increased cTNT, CK-MB and pro-BNP treatment
discontinuation should be avoided. Cardiac events under TKI
treatment may not require a different approach to that of-
fered to a patient without cancer. The only difference is that:
(1) oncological treatment should be temporarily interrupted,
and (2) treatment should be resumed upon recovery along
with permanent cardiac co-medication and close cardiac
monitoring of the patient. In this context, oncologists need
to be aware that some agents, particularly anti-arrhythmic
agents, may exert additive toxicities: e.g. some patients may
receive amiodarone after a cardiac event. Amiodarone and
sotalol are agents that prolong QT intervals, thus increasing
the risk for torsades de pointes. Sunitinib is also an agent
with a possible risk of torsades de pointes. Given together,
the risk for torsades might be higher than with each drug
alone. Changes in toxicity or activity profile may also result
from concomitant cardiac medication. Calcium channel
blockers such as diltiazem or verapamil and again amioda-
rone may be CYP3A4 inhibitors; concomitant use of these
agents with sunitinib may require reduction in the dose of
sunitinib. In most cases, patients can be effectively treated
for both the cardiac event and the oncological condition. It
is of paramount importance to inform the cardiologist about
the necessity of these agents for the patient and about the
change these agents have made to the prognosis of mRCC pa-
tients. Discontinuing RCC treatment should be regarded as
the worst-case scenario.
5.5. Diarrhoea
5.5.1. Mechanism
In contrast to pure VEGF inhibitors such as bevacizumab, diar-
rhoea is a frequent side-effect of multikinase inhibitors. The
underlying mechanism has not been elucidated so far and
may require systematic bowel biopsies and stool analyses
from patients treated with VEGF inhibitors. As both highly
selective VEGFR-TKIs as well as less selective TKIs were
shown to induce diarrhoea; it is also unclear as to whether
this toxicity should be attributed to VEGFR inhibition or off-
target inhibition (e.g. PDGFR, KIT, etc.). VEGF and VEGF recep-
tors were shown to be highly expressed in adult organs,
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 7 2 –1 9 1 181including intestines [99]. Thus, VEGF inhibition may indeed
induce diarrhoea. This assumption is further supported by
data showing that the addition of VEGF(R) inhibitors signifi-
cantly reduced the capillaries network in pancreatic islets
and intestinal villi [100]. All of these findings suggest that
VEGF Inhibition may impair the function of digestive organs
such as intestines and the pancreatic gland. VEGF inhibitors
may cause changes in the bowel mucosa, thereby leading to
diarrhoea. In the intestinal mucosa, even small perturbations
of blood flow can lead to rapid metabolic changes characteris-
tic of ischaemia and hypoxia [101]. Epithelial hypoxia is clin-
ically associated with diarrhoea [102], and changes in the
bowel mucosa are consistent with ischaemic colitis [103].
Other possible mechanisms include changes induced by VEGF
inhibitors in the exocrine pancreas, where VEGF and VEGFR
are highly expressed [99]. Patients with strong VEGFR inhibi-
tor treatment frequently report on fatty stools, and VEGFR
inhibitors were shown to decrease the zymogen granules in
the pancreas (observed in animals under axitinib [2,104])
and to reduce pancreatic islets capillaries [100]. Targets other
than VEGF may be involved as well. For instance, sunitinib is
also a c-kit inhibitor, and KIT is expressed by interstitial cells
of Cajal, the pacemaker cells of the intestine [105]. Cajal cells
are adjacent to the nerve fibres of the myenteric plexus and
regulate rhythmic contractions in the muscle layer. KIT inhi-
bition in interstitial cells of the Cajal could be a potential
mechanism for diarrhoea induced by KIT inhibitors such as
sunitinib and imatinib [106].
5.5.2. Management
The management of TKI-induced diarrhoea includes dietary
measures, probiotics and drugs. Among dietary measures is
the avoidance of food and drinks that may cause bowel move-
ments, such as raw fruits, lactose-containing foods, spicy
foods, foods high in fibre and an increase in bananas, rice,
potatoes, etc. [107]. Another dietary measure is the increased
consumption of grated oxidised apples. A randomised dou-
ble-blinded trial conducted in children revealed that the oxi-
dised apples significantly reduced stool frequency in the
treatment group compared to the control group [108]. Probio-
tics have been shown to prevent diarrhoea in inflammatory
bowel disease [109]. Preclinical data yielded a similar efficacy
in chemotherapy-induced diarrhoea [110,111]. In the clinical
setting, Lactobacillus rhamnosus and fibre were shown to signif-
icantly reduce the incidence of grade 3/4 diarrhoea (37% ver-
sus 22%) in a randomised study in patients with colorectal
cancer and chemotherapy [109]. While the use of probiotics
has never been investigated in TKI patients, individual pa-
tients report considerable benefits.
Although several medical strategies have been established
to manage diarrhoea in general, none of these have been
investigated with regard to TKI-induced diarrhoea. One of
the most commonly used agents is loperamide, which slows
transit by decreasing the tone of the longitudinal muscles
and increasing the tone of circular smooth muscles of the
intestinal wall [112]. This increases the time substances re-
main in the intestines, allowing for more water to be ab-
sorbed. Loperamide also decreases colonic movements and
suppresses the gastrocolic reflux. In mRCC treatment, pa-
tient’s satisfaction with this therapeutic measure has neverbeen investigated and appears to vary. In clinical practice,
some patients report that loperamide successfully controls
higher grades of diarrhoea, while others complain that in
the case of watery stools a slower transit is perceived as a lar-
ger burden than an increased stool frequency. Other medical
strategies to manage or prevent diarrhoea include the use of
budesonide, a topical corticosteroid which was shown to re-
duce bowel inflammation in patients with chemotherapy-in-
duced diarrhoea. Budesonide was shown to reduce the
grade of diarrhoea in >50% in loperamide-refractory patients
treated with chemotherapy [113,114]. There are no data of
budesonide in patients on TKI-induced diarrhoea. Another
agent with unknown benefit in TKI patients is octreotide, a
synthetic somatostatin that is approved for the treatment of
diarrhoea related to vasoactive intestinal peptide (VIP)-secret-
ing tumours and symptoms due to carcinoid syndrome.
Octreotide was shown to decrease the secretion of VIP to pro-
long intestinal transit time and to reduce secretion and in-
crease the absorption of fluid and electrolytes [115]. In
patients with colorectal cancer receiving 5-Fluorouracil (FU)-
based chemoradiation, no difference from placebo was found
[116]. Finally, in patients who complain of bowel movements
during meals or right after, a pancreatic insufficiency induced
by the VEGFR inhibitor might be considered. In this case,
treatment with pancreatin might be helpful (5 meals per
day, 25,000 U pancreatin with each meal).
5.6. Anorexia
5.6.1. Mechanisms
As with fatigue, anorexia is regarded as a common and mul-
tifactorial phenomenon in tumour patients. Anorexia is part
of a syndrome often referred to as anorexia–cachexia and in-
volves metabolic and behavioural factors [117]. Anorexia–ca-
chexia has been strongly linked to an interplay between
cytokines, tumour products that induce lipolysis and/or pro-
tein degradation and neuropeptides [117–119]. TNFa was
shown to induce lipid depletion in white adipose tissue
[120]. Moreover, TNFa induces IL-6 secretion, which was
found to be significantly elevated in patients reporting weight
loss [121]. In a murine model, the cytokine IL-1 was shown to
induce body weight loss [122]. These cytokines appear to in-
duce anorexia by both their peripheral as well as their central
effects [123]. In addition, several neuropeptide dysregulations
have been associated with anorexia. Body weight was shown
to be regulated by interactions between various orexigenic
and anorexigenic central and peripheral neuropeptides
[119]. Whether these interactions are influenced by VEGF
inhibitors has not yet been elucidated.
5.6.2. Management
Several strategies have been investigated regarding their im-
pact on anorexia–cachexia. These include medroxyprogester-
one acetate, eicosapentanoic acid, L-carnitine and
thalidomide. A randomised trial that aimed to identify the
most effective among these strategies revealed the greatest
benefits with a combination of all [124]. Medroxyprogesterone
acetate (MPA) for instance was shown to increase body weight
and appetite in patients with the cachexia–anorexia syn-
drome [125]. The underlying mechanism may involve a
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As MPA has been shown to be increased upon the occurrence
of resistance to TKI treatment in mRCC patients [124], the use
of this agent may potentially act synergistically with TKIs by
preventing or delaying resistance.
5.7. Stomatitis
5.7.1. Mechanisms and presentation
Patients on targeted agents may frequently report changes in
the oral mucosa. The symptoms typically differ from chemo-
therapy-induced stomatitis. It also appears that changes dif-
fer between VEGF-TKIs and mTOR inhibitors. In sunitinib
patients ulcers, taste alterations and cheilitis have been de-
scribed [126]. In contrast, oral changes induced by mTOR
inhibitors appear differently as superficial ulcers similar to
aphthous stomatitis [127].
Dysgeusia or aguesia is quite common in patients under-
going sunitinib treatment. This is a taste disorder where e.g.
the taste of meat may be perceived as sweet or a salty taste
is not sensed at all. Other VEGFR-TKI patients may complain
of oral burning with or without visible signs of inflammation
[2,128,129]. Although stomatitis is completely reversible and
more or less harmless, it is considered as clinically highly rel-
evant since it often impairs the patient’s quality of life. More-
over, permanent stomatitis or dysgeusia may contribute to
chronic refusal of food intake, thereby leading to malnutri-
tion, fatigue and anorexia. As stomatitis resolves rapidly once
the drug is withheld or dose-reduced [126], physicians and pa-
tients might be tempted to accept treatment delays, dose
modifications or even a change of treatment. However, such
strategies may affect the outcome. Little is known of the
mechanism of stomatitis induced by VEGF inhibitors. Apart
from a reduction in the capillary network of the tongue, other
mechanisms may contribute to this AE. Interestingly, oral
changes – e.g. burning mouth syndrome (BMS) – have also
been linked to hypothyroidism [130]. BMS has been character-
ised by oral burning with or without inflammation, frequently
affecting women. In their study, Femiano and colleagues re-
vealed that 85 patients with BMS had thyroid alterations
when compared to 13 patients in the control group. Appar-
ently, patients with BMS are affected by dysgeusia, a phenom-
enon that occurs frequently with tyrosine-kinase inhibitors
[131]. Thyroid hormones have been shown to influence the
maturation and specialisation of the taste buds [132], and it
has been speculated that hypothyroidism could therefore
lead to a reduction in taste. Other investigators [133] have
suggested a dysfunction of the nigrostriatal dopaminergic
pathway that may account for the development of BMS. In a
study on patients with BMS, Lauria and colleagues [134] de-
tected a lower density of epithelial nerve fibres and axonal
degeneration on biopsy of the tongue and suggested that
BMS is caused by a trigeminal small-fibre sensory neuropathy.
In a randomised placebo-controlled study, the topical admin-
istration of clonazepam improved symptoms in two thirds of
BMS patients [135]. Finally, based on the assumption that BMS
involves a dysfunction of the dopaminergic central nervous
system, anti-epileptic drugs have been investigated [136]. Lo-
pez and colleagues reported on a considerable improvement
in BMS after treatment with pregabalin. Other mechanismsthat have been discussed include shifts in the oral mucosa
due to myelosupression [137], shifts in the ecological balance
of oral and gut flora [138], an up-regulation of pro-inflamma-
tory cytokines following cancer treatment [139] followed by
NF-jB and cyclooxygenase-2 up-regulation. It remains un-
clear whether and in what way VEGFR inhibitors are involved
in various processes that have been linked to stomatitis.
5.7.2. Management
Recommendations on how to treat or prevent stomatitis most
commonly stem from experiences made in patients undergo-
ing chemotherapy. General recommendations include, among
others, the avoidance of spicy food, etc., the use of soft tooth-
brushes and appropriate dental hygiene [140]. No general rec-
ommendation exists for the prevention or management of
dysgeusia. A review on drug-related taste disturbances in
the elderly [141] revealed that zinc replacement might be
helpful to enhance taste sensation for sweet, bitter and salty
flavours. Patients with dysgeusia may benefit from niacin and
vitamin A, and the use of mints, sugarless chewing gums and
bicarbonate mouthwashes has been recommended as a palli-
ative measure.
A meta-analysis on prophylactic agents to prevent stoma-
titis [142] identified 10 interventions that have positive effects
on preventing or reducing mucositis. These included amifos-
tine, Chinese herbal mixtures, hydrolytic enzymes such as
trypsin, chymotrypsin, wobe-mugo and pepsin. Moreover, a
recommendation has been made for ice chips. In patients
with haematological malignancies undergoing high-dose che-
motherapy, the use of keratinocyte growth factor-1 (palifer-
min) has been recommended [140] however, no data have
been published with regard to VEGF inhibitors. The same ex-
pert panel also recommended the use of benzydamine for the
prevention of radiation-induced mucositis in patients with
head and neck cancer receiving radiotherapy. Stomatitis in-
duced by mTOR inhibitors appears to be different since it in-
volves immune mechanisms. The management might
therefore be different, and corticosteroids might be helpful
[127].
Treatment of stomatitis may also include mouthwashes
with doxycline and/or sucralfat dissolved in water [143]. Pa-
tients who complain of inflammatory lesions may benefit
from local triamcinolonacetonide. As the management of
stomatitis can prove challenging, changes in treatment
schedules might be considered. Several authors have re-
ported on different modified sunitinib schedules: e.g. from
4 weeks on/2 weeks off to 2 weeks on/1 week off. While
such schedules may help to prevent side-effects
such as stomatitis, no changes in efficacy were observed
[144–146].
5.8. Gastrointestinal perforation
5.8.1. Mechanism and clinical presentation
Gastrointestinal perforations have been rarely reported in pa-
tients with renal cell carcinoma [7]. VEGF has been shown to
be highly important for the integrity of the intestinal mucosa.
Vasoactive agents such as prostaglandins and NO, which are
critical for mucosal defence mechanisms, are activated by
VEGF [147]. Thus, VEGF has been considered a survival factor
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Dose escalaon from 5 to 7 mg b.i.d.
Fig. 1 – Female patient after 3 months on axitinib (no response, no hypertension) and after dose escalation with onset of
hypertension.
Table 3 – Toxicity as a biomarker for outcome.
Agent Side-effect Correlation with outcome
Bevacizumab [196] Hypertension >2 DCR: 91% versus 48% and TTP: 8.1 versus 4.2
Bevacizumab + interferon [8] Hypertension >2 RR: 13 versus 9; OS:41.6 versus 16.2
Sunitinib [14] Hypertension SBP >140, DBP >90 RR: systolic: 55 versus 10; diastolic 57 versus 25%
Sorafenib [197] Hypertension all Shrinkage: 90 versus 33
Axitinib [198] Diastol BP PFS
Sunitinib [16] Hypothyroidism PFS: 10.3 versus 3.6
OS: 18.2 versus 6.6
Sunitinib [199] Hypothyroidism PFS: 575 versus 481 days
Sunitinib [200] Hypothyroidism PFS: 8.55 versus 7.03 mo
Sunitinib + sorafenib [15] Hypothyroidism PFS: 17 versus 10.8; OS: nr versus 13.9
SUN [14] Hypertension ORR: 54.8 versus 8.7%
PFS: 12.5 versus 3.8; OS: 30.9 versus 7.2
DCR, disease control rate; TTP, time to progression; RR, response rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood
pressure; PFS, progression-free survival; OS, overall survival; ORR, objective response rate.
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VEGF inhibition on capillary beds of intestinal villi may di-
rectly contribute to perforation by inducing the regression
of normal blood vessels [100,149]. The occurrence of gas-
trointestinal perforations with VEGF inhibitors has been
linked to the presence of bowel pathologies [148]. Diffuse
abdominal carcinomatosis is associated with a risk of bo-
wel obstruction, increased pressure on weakened bowel
areas and microperforations [150]. Other risk factors in-
clude ulcer, bowel tumour necrosis, diverticulosis, colitis
and prior abdominal or pelvic radiotherapy [151] (Gentech
Inc., Avastin prescribing information, June 2006). Finally, a
reduction in blood flow to the splanchnic vasculature by
thrombosis or vasoconstriction may further increase the
risk of bowel infarction and perforation [152]. Presentation
of gastrointestinal perforation during VEGF inhibitor treat-
ment varies in type and severity, from free air on the
abdominal x-ray which resolves without treatment to
colonic perforation with abdominal abscess and fatal
outcome.5.8.2. Management
Patients with risk factors should be carefully monitored for
clinical signs of perforation, such as abdominal pain, obstipa-
tion, fever, vomiting and leucocytosis [149]. In patients under
suspicion of an increased risk of gastrointestinal perforation
frequent radiographic evaluations for free peritoneal air,
extraluminal contrast and abscess formation may be reason-
able [151]. Physicians should also be aware of potential risks
associated with co-medications such as non-steroidal anti-
inflammatory drugs (NSAIDS). These increase the ratio of
endostatin to VEGF and may further contribute to the occur-
rence of gastrointestinal perforations [153]. In patients who
experience gastrointestinal perforation with VEGF inhibitors,
treatment discontinuation has mostly been recommended.
5.9. Hypothyroidism
5.9.1. Mechanism
Mechanisms of hypothyroidism induced by VEGFR inhibitors
may include both on- and off-target inhibition. VEGFR is
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gland which are also able to synthesise VEGF [58,154–160].
Thus, VEGF inhibitors may induce capillary regression in the
thyroid [64,100], leading to the destruction of normal thyroid
cells. In addition, sunitinib was shown to induce hypothyroid-
ism by inhibiting iodine uptake [161] and peroxidase activity
[162]. It remains unclear whether off-target(s) inhibition
may also contribute to hypothyroidism. Multikinase inhibi-
tors such as sunitinib were shown to strongly inhibit RET/
PTC signalling, thus being potentially beneficial in the man-
agement of thyroid cancer.
5.9.2. Management
Patients treated with VEGF inhibitors should be monitored
for hypothyroidism before and at regular intervals during
treatment. Both clinically overt and subclinical hypothyroid-
ism may occur. According to the clinical practice guidelines
for hypothyroidism in adults [163], the standard treatment
is replacement with L-thyroxine in patients with persistent
TSH levels >10 mIU/L. In patients with subclinical hypothy-
roidism (defined as TSH <10 mIU/L), 92% would be consid-
ered for hormone replacement. These guidelines have
been established to prevent the long-term damage caused
by hypothyroidism in otherwise healthy patients. How rele-
vant are these recommendations in patients with mRCC,
and what are the clinical implications for the management
of TKI-induced hypothyroidism? This is particularly of inter-
est since several authors have reported on an antitumour
effect of hypothyroidism. Hypothyroidism was shown to in-
hibit tumour cell proliferation in various cancer cells and
animal models [164–167]. Moreover, hypothyroidism was
shown to inhibit neoangiogenesis and to improve outcome
in patients with head and neck cancer [168,169]. Thus, the
question arises as to whether we should tolerate TKI-in-
duced hypothyroidism to some extent. Physicians need to
be aware that hypothyroidism has considerable effects on
cardiac function, including impaired relaxation and ventric-
ular filling, increase in peripheral vascular resistance and
increased diastolic blood pressure as well as reduced ejec-
tion at exercise [170]. Therefore, hormone replacement ap-
pears to be mandatory in the majority of patients. In this
context it is important to note that triiodothyronine (T3)
is the relevant hormone for the cardiac myocyte. Interest-
ingly, T3 supplementation was shown to be 50 times less
proliferative and less pro-angiogenic than T4, the ‘bad
guy’ among thyroid hormones [171]. An advantage of T3
replacement would also be that it reduces T4 levels; how-
ever, T3 replacement is difficult in clinical practice due to
the short half-life of available formulations. This problem
could potentially be solved by the use of a combination of
T3 and T4. It has been stated recently that combined T3
and T4 replacement may represent a more personalised ap-
proach to treat hypothyroidism [172].
5.10. Hand–foot syndrome
5.10.1. Presentation and mechanism
HFS has been reported to occur between days 14 and 28 of
VEGF inhibitor treatment [173]. According to the Common
Terminology Criteria for Adverse Events (CTCAE Version4.0, 2009), patients with grade 1 HFS present with minimal
skin changes or dermatitis (erythema, oedema or hyperker-
atosis) without pain. In contrast, patients with grade 2 HFS
complain of painful skin changes (peeling, blisters, bleed-
ing, oedema and hyperkeratosis) that may limit activities
of daily living. Finally, grade 3 HFS has been defined as
the presence of severe skin changes associated with severe
pain and limited self-care.
Several histopathological changes have been described
by Yang and colleagues [174]. The most common include
intracytoplasmic eosinophilic bodies reflecting keratinocyte
damage, keratinocyte vacuolar degeneration and confluent
keratinocyte necrosis associated with intraepidermal cleav-
age. In addition, an accelerated epidermal cell replication
and increased keratinocyte proliferation has been described
by the authors. So far, the exact mechanism of HFS with
multikinase inhibitors has not been elucidated. The sever-
ity of clinical presentation appears to be correlated with
drug exposure. Discussed mechanisms include: (1) an in-
creased drug concentration in the capillaries at the
papillary dermis, (2) interference by VEGF–PDGFR inhibition
associated with pericyte-mediated endothelial survival
mechanisms, leading to damage of the capillary endothe-
lium in hands and feet [82], (3) an impaired vascular
repair leading to keratinocyte apoptosis and inflammation
and (4) a direct effect of the drug in eccrine sweat
glands.
5.10.2. Management
The management of HFS in patients treated with VEGF
inhibitors has been reviewed by Anderson and colleagues
[175]. Prophylactic measures include pedicure before treat-
ment to remove hyperkeratosis, emollients, topical exfoliat-
ing products (urea-based and salicylic-acid-based),
protection of pressure-sensitive areas (e.g. shoes with soft
insoles) and perhaps systemic administration of pyridoxine,
glucocorticosteroids and cycloogygease-2 inhibitors. The
authors also highlight the importance of frequent and early
collaborations between oncologists and dermatologists.
Dose reductions and treatment interruptions may be tem-
porarily required. The authors recommend a dose reduction
at first occurrence of grade 2 until HFS resolves to grade 0–1
and to increase the dose afterwards; if no improvement to
grade 0–1 occurs, treatment interruption for 7 days may be
necessary. The dose may then be escalated depending on
the HFS grade. In the case of grade 3 HFS, recommenda-
tions regarding dosing include the interruption of TKI treat-
ment for 7 days (until toxicity resolves to grade 0–1) and to
resume treatment at a reduced dose. If toxicity is main-
tained at grade 0–1 at reduced dose, dose escalation may
be recommended. In the case of recurrent grade 3 HFS,
treatment should be resumed at a reduced dose after recov-
ery without further dose escalations. According to the
authors, combinations of cortisone creams and topical anti-
biotics might be recommended in cases of severe HFS.
These recommendations have been made for patients trea-
ted with sorafenib. Although they may also apply to pa-
tients with other VEGFR–TKIs, individual modifications
according to the clinical presentation, the type of drug
and the drug schedule may be reasonable.
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5.11.1. Mechanisms
Myelotoxicity of tyrosine kinase inhibitors has been linked to
their ability to inhibit various targets. (1) They inhibit KIT sig-
nalling: KIT receptors are expressed on haematopoietic pro-
genitor cells and are involved in their growth and
differentiation. Sunitinib was shown to inhibit phosphoryla-
tion of the KIT receptor and cell proliferation [176]. (2) VEGF
inhibition may also account for myelotoxicity. Gerber and col-
leagues [177] described a regulatory loop by which VEGF con-
trols survival of haematopoietic stem cells. Interestingly,
ligands selective for VEGF and VEGFR-2 as well as VEGFR-1
agonists were shown to rescue survival of VEGF-deficient hae-
matopoietic stem cells. Moreover, VEGF was shown to be in-
volved in the formation of myeloid and erythroid colonies
from progenitor cells [178]. (3) Inhibition of FLT-3 on haemato-
poietic stem cells and PDGFR signalling has also been linked
to myelotoxicity [179,180]. (4) Finally, it has been suggested
that thrombocytopenia might be the result of hypertension
[181] or may be caused by drug-induced immune thrombocy-
topenia [182].
5.11.2. Management
In caucasian populations, myelotoxicity is seldom a dose-
or treatment-limiting toxicity. In the case of grade 2 neutro-
penia or thrombocytopenia, dose adjustments are rarely
necessary. The occurrence of grade P3 myelotoxicity has
been reported to occur more frequently in Asian patients
[183]. In the case of grade 3 neutropenia or thrombocytope-
nia temporary treatment interruptions may be required. In
the case of sunitinib, dose modifications may depend on
the day on which grade 3 myelotoxicity is observed. If ob-
served on day 28 of treatment, prior to the 2-week rest, pa-
tients may not necessarily require dose reduction in the
next course because neutropenia and thrombocytopenia
are usually short-lived and tend to resolve during the
2 weeks off treatment; blood cell counts should be repeated
on day 1 of the next course, and if neutrophils and throm-
bocytes return to normal levels, careful continuation at the
same dose level might be possible [107]. Blood cell counts
should be obtained every 2 weeks, and in the case of re-
peated grade 3 myelotoxicity, treatment should be withheld
for a few days until toxicity is grade 2 or less. In the case of
recurring grade 3 myelotoxicity, dose reduction should be
recommended after recovery [184].
6. Toxicities as biomarkers for successful
outcome
Several retrospective studies have identified specific side-
effects to be strongly associated with outcome. Table 3
summarises these findings. The most common side-effect
that has been associated with outcome is hypertension.
Additional toxicities that were shown to correlate with
the outcome are myelotoxicity [185,186], HFS [186] and fa-
tigue/asthenia [187]. What is the biological basis for this
correlation? The toxicity may reflect that (1) the mecha-
nism of action may be appropriate in the individualpatient, (2) the chosen drug has a high selectivity and ade-
quate potency to hit the target, (3) the tumour is depen-
dent on the inhibited pathway and (4) the drug exposure
is appropriate; this may also be influenced by the presence
or absence of specific single-nucleotide polymorphisms
that influence pharmacokinetic and pharmacodynamic pro-
cesses [188,189].
The potential association of toxicities and outcome has
several clinical implications and raises three major ques-
tions. (1) Should we treat the toxicity, or would this impair
the outcome? In this context, correction of hypertension
has been well studied. While the occurrence of hyperten-
sion appears to be predictive, treating hypertension does
not appear to impair the outcome. In a retrospective analy-
sis on hypertension as a predictive factor for outcome with
sunitinib treatment, Szmit and colleagues [190] reported
that patients who required at least three antihypertensive
agents had the longest PFS. Thus, managing hypertension
is not only mandatory for the patient’s safety, but it also
does not appear to affect the outcome. These findings
may, however, vary depending on the toxicity observed.
As hypothyroidism was shown to be associated with the
inhibition of angiogenesis [168,169] and cell proliferation
[164], maintaining a state of (preferably) T4-hypothyroidism
may to some extent be beneficial for the outcome. In this
context, TSH levels above the upper limit of normal and be-
low the threshold for cardiac impairments (>10 mmol/L)
may be acceptable. (2) Should we adjust the dose until tox-
icity is observed (treating according to toxicity)? In the axi-
tinib dose-titration trial, patients with dose titration and
those who did not require dose titration as assessed by
the occurrence of hypertension had a better outcome when
compared to patients without dose titration [19]. Fig. 1
shows the computed tomography (CT) scans of a female
mRCC-patient who did not experience either hypertension
(or other dose-limiting toxicities) or remission with axitinib
5 mg bid. Only upon dose adjustment to 7 mg bid did the
patient develop hypertension and a reduction in the size
of metastasis. These findings suggest that we may consider
a potential benefit of the ‘treat to toxicity’ approach. Natu-
rally, such strategies should only be considered in the ab-
sence of other dose-limiting toxicities and require careful
monitoring. (3) What is the role of agents given to manage
the toxicity? Do these agents modify the outcome? We can-
not rule out that agents given against the toxicity may have
additional benefits against tumour progression. For in-
stance, some antihypertensive agents were shown to exert
interesting antitumour properties. Beta-blockers, for exam-
ple, were shown to induce apoptosis in endothelial cells
[191] and have been established as standard of care for
infantile haemangiomas [192]. Moreover, several reports
have demonstrated that angiotensin II stimulates growth
and migration of cancer cell lines and induces angiogenesis
through up-regulation of VEGF; interestingly, this effect can
be inhibited by angiotensin-receptor blockers (ARBs) [193].
Losartan, an ARB, was shown to stimulate pro-apoptotic
signalling pathways in various tumour types [194,195]. Fi-
nally, calcium-channel blockers have been shown to reduce
the proliferation and migration of glioma cells [196].
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VEGF inhibitors have substantially improved the outcome of
patients with metastatic renal-cell carcinoma. Incidence
and severity of side-effects may vary between agents and de-
pend on the mode of action of the chosen drug as well as on
individual patient-related factors. Physicians need to be
aware of both patient- and agent-related risks that may occur
during treatment in order to choose the best individual treat-
ment and maintain the patient’s safety and quality of life. It
should be considered that the majority of side-effects are
manageable with proactive supportive measures and close
monitoring of the patient. Dose reductions, treatment inter-
ruptions and discontinuation should be avoided whenever
possible.
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